scholarly journals Translational precision medicine: an industry perspective

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Dominik Hartl ◽  
Valeria de Luca ◽  
Anna Kostikova ◽  
Jason Laramie ◽  
Scott Kennedy ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Drug Discovery ◽  
Precision Medicine ◽  
Paradigm Shift ◽  
Development Process ◽  
New Technologies ◽  
Traditional Approach ◽  
Drug Discovery And Development ◽  
Development Face ◽  
Digital Biomarkers

AbstractIn the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective.

Translational Medicine – A Paradigm Shift in Modern Drug Discovery and Development

2020 ◽  
pp. 333-345
Author(s):  
Giora Z. Feuerstein ◽  
Salvatore Alesci ◽  
Frank L. Walsh ◽  
J. Lynn Rutkowski ◽  
Robert R. Ruffolo
Keyword(s):  
Drug Discovery ◽  
Paradigm Shift ◽  
Translational Medicine ◽  
Drug Discovery And Development ◽  
Modern Drug

Incorporating the assessment of abuse liability into the drug discovery and development process

2003 ◽  
Vol 70 (3) ◽  
pp. S73-S85 ◽  
Author(s):  
Robert S. Mansbach ◽  
Douglas E. Feltner ◽  
Lisa H. Gold ◽  
Sidney H. Schnoll
Keyword(s):  
Drug Discovery ◽  
Development Process ◽  
Abuse Liability ◽  
Drug Discovery And Development

Making medicines

2018 ◽  
Vol 32 (5) ◽  
pp. 302-311 ◽  
Author(s):  
Elizabeth K. McClain ◽  
Yolanda Johnson-Moton ◽  
Bryan Larsen ◽  
Rebecca J. Bartlett Ellis ◽  
Eric Niederhoffer
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Development Process ◽  
Course Development ◽  
Educational Partnerships ◽  
Collaborative Process ◽  
Drug Discovery And Development ◽  
Online Module ◽  
Systems Thinking Approach

The approach to building innovative partnerships between academia and the pharmaceutical industry has expanded to investigate collaborations that offer meaningful outcomes beyond discovery and increased productivity. This case study uses a systems thinking approach to guide the process and analyse the outcome of a partnership undertaken by one pharmaceutical company and academia. The collaborative process established three tiers of evolution over a 3-year period. The outcome was an online module–based course, entitled ‘Making Medicines: The Process of Drug Development’, that provides information about the drug discovery and development process. Both the course development and the final product serve as a useful case study of how collaboration between academia and industry might be achieved. The development process itself is proposed as an appropriate approach for building educational partnerships.

scholarly journals The Stages of Drug Discovery and Development Process

2019 ◽  
Vol 7 (6) ◽  
pp. 62-67 ◽  
Author(s):  
Amol B Deore ◽  
Jayprabha R Dhumane ◽  
Rushikesh Wagh ◽  
Rushikesh Sonawane
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Drug Development ◽  
Development Process ◽  
Regulatory Requirements ◽  
Drug Discovery And Development ◽  
Biological Targets ◽  
New Drug ◽  
Initial Discovery ◽  
New Research

Drug discovery is a process which aims at identifying a compound therapeutically useful in curing and treating disease. This process involves the identification of candidates, synthesis, characterization, validation, optimization, screening and assays for therapeutic efficacy. Once a compound has shown its significance in these investigations, it will initiate the process of drug development earlier to clinical trials. New drug development process must continue through several stages in order to make a medicine that is safe, effective, and has approved all regulatory requirements. One overall theme of our article is that the process is sufficiently long, complex, and expensive so that many biological targets must be considered for every new medicine ultimately approved for clinical use and new research tools may be needed to investigate each new target.  From initial discovery to a marketable medicine is a long, challenging task. It takes about 12 - 15 years from discovery to the approved medicine and requires an investment of about US $1 billion. On an average, a million molecules screened but only a single is explored in late stage clinical trials and is finally made obtainable for patients. This article provides a brief outline of the processes of new drug discovery and development.   

scholarly journals Spread and Dynamics of COVID-19 in the Kingdom of Saudi Arabia and Four Other Countries in the Early Phase: A Study for the Development of the Advanced Health System

2021 ◽  
Author(s):  
Shahanavaj Khan ◽  
Asimul Islam ◽  
Ahmad Firoz ◽  
Anis Ahmad Chaudhary ◽  
Mohammad Amjad Kamal ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Saudi Arabia ◽  
Health Policy ◽  
Drug Discovery ◽  
Early Phase ◽  
Kingdom Of Saudi Arabia ◽  
Drug Discovery And Development ◽  
First Case ◽  
Daily Report ◽  
The World

Abstract BackgroundThe epidemic of 2019 novel coronavirus (SARS-CoV-2) is challenge to the world which was at first confirmed in the Wuhan city of China in December 2019. It was declared a pandemic by the World Health Organization (WHO) in March 2020. In the current work we evaluated effect of health policy of Saudi Arabia for the management of COVID-19 pandemic in early phase and compared to other four countries. MethodBased on the Ministry of Health, Kingdom of Saudi Arabia (KSA) data, the summary of daily report of COVID-19 was prepared from 02 March to 30 April 2020. Further, the daily report of enhancement in cases and recovery of the patients was also summarized. Moreover, the incidence, death and recoveries of COVID-19 cases in KSA were compared with major infected country including China, Italy, Spain and United State of America (USA). The important role of artificial intelligence was shown for the development of drug targets against to infectious diseases Results In KSA, the first case of COVID-19 was reported on 02 March 2020. Since then, it has affected 22,753 persons till the end of the April 2020. Also, the results showed that the infection rate of COVID-19 increased continuously during the current period of study in KSA. Nevertheless, the rate of death due to COVID-19 is much less with comparison to China, Italy, Spain, and USA due to good medical facilities along with quick action by the government of KSA after the emergence of first case. There is a dire need to develop new platforms and approaches to combat new and old diseases including COVID-19 at warp speed when compared to traditional approaches. DeepDrug’s approach to drug discovery and development showed brighter future towards the discovery of novel drugs against infectious diseases including COVID-19.ConclusionCurrently, there is higher probability of COVID-19 spread at any place. Therefore good health policy, precautionary measures and medical facility of whole nations should be excellent to combat against the COVID-19 pandemic until the reliable vaccine or antiviral drug developed for the proper treatment of virus. The artificial intelligence (AI) based available process might be very helpful for the drug discovery and development against of old and newly discovered diseases including COVID-19.

Sign in / Sign up

Export Citation Format

Share Document